Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 55 clinical trials
Cabozantinib for Patients With Recurrent or Progressive Meningioma

A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

neutrophil count
renal function
karnofsky performance status
hysterectomy
measurable disease
  • 0 views
  • 08 Jul, 2022
  • 1 location
Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients

In the proposed trial, patients will be administered ribociclib prior to surgical resection of their tumor. Patients will be enrolled in time-intervals sequentially (non-randomized). All patients will be orally-administered 5 doses of LEE011 (900 mg/d) with the final dose occurring at one of 3 intervals before brain tumor resection.

MRI
potassium
liver metastases
tamoxifen
ribociclib
  • 250 views
  • 27 Jan, 2022
  • 1 location
An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma

This research study is studying targeted immunotherapies as a possible treatment for recurrent meningioma. The names of the study interventions involved in this study are nivolumab and

biologic agent
mirena
ipilimumab
corticosteroids
ebrt
  • 242 views
  • 25 Mar, 2022
  • 1 location
Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas

This phase I trial studies how well gallium Ga 68-DOTATATE positron emission tomography (PET)/computed tomography (CT) works in predicting tumor growth in patients with meningiomas. Giving

ct scan
residual tumor
dotatate
positron emission tomography
  • 26 views
  • 08 Feb, 2022
  • 1 location
Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC

The goal of this study is to propose the first direct comparison of Ga-68-DOTATATE PET and Ga-68-DOTATOC PET in patients with meningioma.

dotatoc
dotatate
somatostatin
  • 3 views
  • 19 Apr, 2022
  • 1 location
Treatment of Recurrent or Progressive Meningiomas With the Radiolabelled Somatostatin Antagonist 177Lu-satoreotide

Meningiomas are known to be the most frequent intracranial neoplasms and account for approx. 25-33% of all intracranial tumours.Targeted radionuclide therapy with radiolabelled somatostatin

dotatoc
karnofsky performance status
peptide receptor radionuclide therapy
ct scan
somatostatin
  • 0 views
  • 18 Aug, 2021
  • 1 location
Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma

or residual high-risk Ga-DOTATATE PET-MRI positive meningioma. Ga-DOTATATE PET-MRI scans will be obtained prior to initiation of Lutathera treatment and 6 months after the initiation of Lutathera

biologic agent
MRI Scan
lymphopenia
residual tumor
platelet count
  • 40 views
  • 04 Jun, 2022
  • 2 locations
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or

tumor cells
vismodegib
gsk2256098
  • 4 views
  • 25 Jul, 2022
  • 511 locations
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy

This phase II trial studies how well lutathera works in treating patients with meningioma that cannot be treated with surgery (inoperable) and is growing, spreading, or getting worse

  • 5 views
  • 24 May, 2022
  • 1 location
Intravenous Tranexamic Acid Reducing Intraoperative Blood Loss in Huge Meningiomas Resection

Intra-operative blood loss of huge meningioma resection patients on average was over 1000ml. Intra-operative massive hemorrhage was associated with longer hospital of stay, higher expense, and

tranexamic acid
  • 0 views
  • 21 Jul, 2022
  • 1 location